Comparative Pharmacology
Head-to-head clinical analysis: AQUASOL A versus VITAMIN A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQUASOL A versus VITAMIN A.
AQUASOL A vs VITAMIN A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin A is essential for vision, epithelial differentiation, bone growth, reproduction, and immune function. It acts as a retinol-binding protein that regulates gene expression through retinoic acid receptors.
Vitamin A (retinol) is converted to retinal and retinoic acid, which bind to nuclear receptors (RARs and RXRs) to regulate gene expression involved in cell growth, differentiation, and vision.
100,000 to 200,000 IU intramuscularly once monthly for prophylaxis; 50,000 to 100,000 IU intramuscularly daily for 3 days for severe deficiency.
Adults: 10000-50000 IU/day orally for deficiency; up to 100000 IU/day for severe deficiency short-term. Intramuscular: 50000 IU daily for 3 days, then 50000 IU weekly for 2-3 months.
None Documented
None Documented
Clinical Note
moderateVitamin A + Digoxin
"Vitamin A may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateVitamin A + Digitoxin
"Vitamin A may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateVitamin A + Deslanoside
"Vitamin A may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateVitamin A + Acetyldigitoxin
"Vitamin A may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 24-48 hours (mean 36 h); prolonged in renal impairment; clinical context: steady-state achieved in ~5-7 days with daily dosing.
The terminal elimination half-life of vitamin A is variable, ranging from 10 to 100 days due to extensive storage in the liver; in individuals with adequate hepatic stores, the half-life is approximately 50–100 days, but in deficiency states, it may be shorter (10–20 days). Clinically, this long half-life supports once-daily dosing for chronic therapy.
Renal: ~60% as metabolites; fecal: ~30% as unchanged drug and metabolites; biliary: ~10%.
Vitamin A is eliminated primarily via biliary excretion into feces as metabolites (approximately 80–90%), with renal excretion accounting for less than 10% of unchanged drug and metabolites. A small fraction undergoes enterohepatic circulation.
Category C
Category C
Vitamin A
Vitamin A